Mon Sep 09 16:05:00 UTC 2024: ## ArriVent BioPharma Reports Positive Interim Data for Firmonertinib in EGFR PACC Mutant NSCLC
**NEWTOWN SQUARE, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE)** – ArriVent BioPharma, Inc. (Nasdaq: AVBP) announced positive interim data from its global Phase 1b FURTHER trial for firmonertinib, a novel EGFR inhibitor, in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations.
The data, presented at the IASCLC 2024 World Conference on Lung Cancer, showed robust systemic and CNS anti-tumor activity for firmonertinib in this patient population.
Key findings include:
* **81.8% objective response rate (ORR) by BICR** and **63.6% confirmed ORR by BICR** at the 240 mg dose.
* **46.2% confirmed ORR in CNS metastases.**
* **90.9% of patients with confirmed responses remained on study** with a median duration of response not yet reached.
“These data are the first to demonstrate robust systemic and CNS anti-tumor activity for firmonertinib in a PACC mutant population,” said Bing Yao, Chairman and Chief Executive Officer of ArriVent. “We believe that the generally well-tolerated safety profile and response duration seen to date reinforce the therapeutic potential of firmonertinib to be an effective oral, chemotherapy-free treatment for this underserved patient population.”
Dr. Xiuning Le, Associate Professor of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, highlighted the encouraging data, stating that firmonertinib “suggests rapid and robust anti-tumor activity across PACC mutations, which is similar to that observed for firmonertinib in exon 20 insertions. Moreover, the apparent high CNS activity points to firmonertinib as a promising potential new therapy for frontline patients with PACC mutations including those with CNS disease.”
Firmonertinib is currently being studied in a global Phase 3 trial for first-line NSCLC patients with EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and a global Phase 1b study evaluating firmonertinib in patients with EGFR PACC mutations (FURTHER; NCT05364073).
ArriVent will host a virtual webinar on September 9, 2024 at 4:30 pm ET to discuss these interim analyses. To register for the event, please visit [link to registration website].
First Piper 